This phase 3 study tests a drug called IMP4297 (a PARP inhibitor) as a maintenance treatment for people with advanced ovarian cancer (stage III or IV) who have finished their first round of chemotherapy. The goal is to see if taking this drug daily can delay the cancer from comin…
Phase: PHASE3 • Sponsor: Impact Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC